Search - tctmd.com

Displaying 821 - 840 of 1055

Sort: Relevancy | Date

Presentation TCT 2012

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Presenter: Adam de Belder

October 26, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

Presentation TCT 2012

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Presenter: Robert Byrne

October 26, 2012

Presentation TCT 2012

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

Presenter: Philip Urban

October 25, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

Presentation TCT 2012

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Manel Sabate

October 25, 2012

Presentation TCT 2012

Bioabsorbable Stent Components and Stents

Presenter: Shigeru Saito

October 24, 2012

Presentation TCT 2012

TCT-47. Two-year Clinical Outcome of the TWENTE Trial, A Randomized Controlled Trial Comparing Second-generation Zotarolimus-eluting Resolute Stents vs. Everolimus-eluting...

Presenter: Clemens von Birgelen

October 23, 2012

Presentation TCT 2012

TCT-46. Comparison of Polymer-Free BioFreedom™ Stents with Durable Polymer Taxus Liberté™ Stents: 3-Year Results from the BioFreedom First-in-man Trial

Presenter: Eberhard Grube

October 23, 2012

Presentation TCT 2012

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

Presenter: Patrick Serruys

October 23, 2012

Presentation TCT 2012

Nanoparticle-Based Stents 2: FOCUS np (Envision Scientific) Program Update

Presenter: Ashok Seth

October 23, 2012

Presentation TCT 2012

Nanoparticle-Based Stents 1: Mitsui (Meril Life Sciences) Program Update

Presenter: Ricardo Costa

October 23, 2012

Presentation TCT 2012

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Presenter: Ajay Kirtane

October 23, 2012

Presentation TCT 2012

Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK): DREAMS 2-Year Results

Presenter: Michael Haude

October 23, 2012

Presentation TCT 2012

Everolimus-Eluting Stents: SPIRIT and PLATINUM Update

Presenter: Gregg Stone

October 22, 2012

Presentation TCT 2012

Bioabsorbable Stents

Presenter: Hector Garcia-Garcia

October 22, 2012

Advertisement

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Bioabsorbable Stent Components and Stents

TCT-47. Two-year Clinical Outcome of the TWENTE Trial, A Randomized Controlled Trial Comparing Second-generation Zotarolimus-eluting Resolute Stents vs. Everolimus-eluting...

TCT-46. Comparison of Polymer-Free BioFreedom™ Stents with Durable Polymer Taxus Liberté™ Stents: 3-Year Results from the BioFreedom First-in-man Trial

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

Nanoparticle-Based Stents 2: FOCUS np (Envision Scientific) Program Update

Nanoparticle-Based Stents 1: Mitsui (Meril Life Sciences) Program Update

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK): DREAMS 2-Year Results

Everolimus-Eluting Stents: SPIRIT and PLATINUM Update

Bioabsorbable Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content